Researchers from Zhengzhou University and affiliated organizations published data from a study that aimed to assess the expression levels of histone modifier enzymes in esophageal squamous cell carcinoma (ESCC).
Bispecific T-cell engager (BiTE) antibodies have shown efficacy in hematological malignancies and are being tested in a variety of solid tumors. Other strategies including bispecific antibodies in combination with monoclonal antibodies or targeting two different immune checkpoints on T cells are also undergoing clinical development.
Right open reading frame kinase 2 (RIOK2) plays an essential role in ribosome assembly and cell growth, survival and stress responses. Research has linked RIOK2 to tumor progression and poor prognosis in several types of cancer such as breast, lung, prostate or hematological tumors.
The research on glioblastoma requires the development of new preclinical murine models. The GL261 cell line forms glioma-like tumors in a reliable manner when transplanted intracranially, but these tumors do not completely mimic human glioblastoma. This model responds well to immune checkpoint inhibitors (ICIs), but ICIs have shown limited efficacy in some clinical trials.
Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of cancer management. However, acquired resistance and response variability point to rational combination strategies as the goal to achieve significant improvements in the field. Investigators at the National Cancer Center of Japan have found that stimulators of the innate immune response unexpectedly activated suppressive cells of the innate immune system.
The scientific establishment has launched a fight back against the Trump administration and the slew of executive orders that threaten to dismantle research funding, with a warning that the next month could be critical for the future of U.S. science.
Glenmark Pharmaceuticals Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 receptor-associated kinase 3 (IRAK-3; IRAK-M) targeting moiety via linker reported to be useful for the treatment of cancer.
Bial-Portela & Ca SA has identified orexin OX1 receptor antagonists reported to be useful for the treatment of cognitive, sleep, anxiety and eating disorders, depression, obesity, schizophrenia, substance abuse and dependence, among others.
2A Biosciences Inc. has synthesized tryptamine derivatives acting as 5-HT2A receptor agonists reported to be useful for the treatment of psychiatric, neurodegenerative, neurodevelopmental, inflammatory and eye disorders.
RSS
